Analysts Anticipate Assembly Biosciences Inc (ASMB) to Post -$1.07 EPS

Wall Street brokerages predict that Assembly Biosciences Inc (NASDAQ:ASMB) will report ($1.07) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Assembly Biosciences’ earnings. The highest EPS estimate is ($0.96) and the lowest is ($1.15). Assembly Biosciences reported earnings per share of ($0.80) during the same quarter last year, which suggests a negative year-over-year growth rate of 33.8%. The business is expected to issue its next quarterly earnings results on Monday, May 6th.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.37) per share for the current fiscal year, with EPS estimates ranging from ($5.19) to ($3.74). For the next year, analysts anticipate that the company will report earnings of ($5.33) per share, with EPS estimates ranging from ($5.80) to ($4.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $3.69 million.

ASMB has been the topic of a number of research analyst reports. BidaskClub upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Chardan Capital restated a “hold” rating and issued a $30.00 target price on shares of Assembly Biosciences in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Hold” and an average target price of $43.00.

NASDAQ:ASMB traded down $0.28 on Friday, reaching $15.19. The company’s stock had a trading volume of 607,901 shares, compared to its average volume of 311,168. Assembly Biosciences has a 12-month low of $13.13 and a 12-month high of $48.91. The company has a market capitalization of $388.10 million, a P/E ratio of -3.82 and a beta of 1.60.

Hedge funds have recently bought and sold shares of the stock. Tibra Equities Europe Ltd purchased a new stake in shares of Assembly Biosciences in the 1st quarter valued at $918,000. Man Group plc raised its holdings in shares of Assembly Biosciences by 19.6% in the 3rd quarter. Man Group plc now owns 36,042 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 5,904 shares during the period. Marshall Wace LLP purchased a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $11,224,000. Victory Capital Management Inc. raised its holdings in shares of Assembly Biosciences by 3.4% in the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after buying an additional 17,669 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Assembly Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc now owns 1,051,454 shares of the biopharmaceutical company’s stock valued at $39,052,000 after buying an additional 238,952 shares during the period. Hedge funds and other institutional investors own 83.77% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Further Reading: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.